

Tuesday Pre-Market Top Gainers \$OCX \$MCEP

By winkler · December 15, 2020

TL;DR

This blog post highlights the top pre-market gainers for Tuesday, focusing on stocks such as OncoCyte Corporation (OCX), Anavex Life Sciences Corp. (AVXL), and Anchiano Therapeutics Ltd. (ANCN). It provides insights into recent developments and news affecting these companies, particularly in the healthcare and biotechnology sectors.

TABLE OF CONTENTS

[News](#)

[Live Stream](#)

[Research / Recap Video](#)

[Watchlist](#)

News

[USA Corona Virus](#)

Live Stream

<https://youtu.be/C4eeCLvozuM>

Research / Recap Video

10:33AM bah9681 Here is another TOS thing that they don't disclose: They run a report on traders that place over 390 trades a day (to include cancelled orders) and will flag you and threaten commissions of \$2

Watchlist

OCX [AMEX]
OncoCyte Corporation
Healthcare Biotechnology USA

70% 138mc 57f

Dec-15-20 01:33AM	Burning Rock Announces an Exclusive in-Licensing of a Risk Stratification Test for Early Stage Lung-Cancer Patients from Oncocyte in China GlobeNewswire
Dec-07-20 04:05PM	Oncocyte Corporation Hosting Key Opinion Leader Call on Proprietary Molecular Tests for Cancer Treatment Selection GlobeNewswire

AVXL [NASD]
Anavex Life Sciences Corp.
Healthcare Biotechnology USA

40% 313mc 58f

Dec-15-20 07:00AM	Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome GlobeNewswire
Nov-30-20 07:00AM	Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders GlobeNewswire
Nov-27-20 10:00AM	Where Do Hedge Funds Stand On Anavex Life Sciences Corp. (AVXL)? Insider Monkey

ANCN [NASD]
Anchiano Therapeutics Ltd.
Healthcare Biotechnology USA

200% 11mc 3f

Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need

Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel

CAMBRIDGE, Mass. and TEL-AVIV, Israel, Dec. 15, 2020 (GLOBE NEWSWIRE)

Free Gap Scanner + Win 2 Free Stocks ☐ (Each Up To \$1600) ☐ <http://enzlo.com/webull>

Best Savings Account Ever! ☺ Win \$10 Million - Use Code: WINKLER ☐ <http://enzlo.com/save>

Watchlist ☐ <https://tradejournal.co/post/tuesday-pre-market-top-gainers-ocx-mcep/>

FAQ

What are the top pre-market gainers mentioned?

The top pre-market gainers include OncoCyte Corporation (OCX), Anavex Life Sciences Corp. (AVXL), and Anchiano Therapeutics Ltd. (ANCN).

What recent news is associated with OncoCyte Corporation?

OncoCyte Corporation recently announced an exclusive in-licensing of a risk stratification test for early-stage lung cancer patients in China.

What significant milestone did Anavex Life Sciences achieve?

Anavex Life Sciences announced that its drug ANAVEX®2-73 (Blarcamesine) met primary and secondary endpoints in a Phase 2 clinical trial for treating adult patients with Rett Syndrome.

What is Anchiano Therapeutics' focus?

Anchiano Therapeutics is advancing its lead compound CM-101, a first-in-class anti-CCL24 antibody, for fibrosis-related diseases with significant unmet medical needs.

How can I access the watchlist mentioned in the blog?

You can access the watchlist through the provided link in the blog post.